

Supplementary Table 1 Demographic and clinical characteristics.

	Study 1	Study 2		Study 3
	(60–64 y; PPSV23-naive) n^a=470	Cohort 1 (60–64 y; PPSV23-naive) n^a=411	Cohort 2 (50–59 y; PPSV23-naive) n^a=388	(≥70 y; PPSV23 ≥5 y before enrollment) n^a=431
Mean ± SD age, ^b y	61.7±1.4	61.8±1.4	54.4±2.9	76.7±4.7
Female, n (%)	277 (58.9)	220 (53.5)	240 (61.9)	204 (47.3)
Race, n (%)				
White	445 (94.7)	396 (96.4)	371 (95.6)	417 (96.8)
Black/African American	17 (3.6)	4 (1.0)	12 (3.1)	8 (1.9)
Asian	1 (0.2)	3 (0.7)	4 (1.0)	2 (0.5)
Other	7 (1.5)	8 (1.9)	1 (0.3)	4 (0.9)
Ethnicity, n (%)				
Hispanic or Latino	12 (2.6)	9 (2.2)	8 (2.1)	3 (0.7)
At-risk population, ^c n (%)				
Cardiovascular disease	28 (6.0)	18 (4.4)	9 (2.3)	73 (16.9)
Pulmonary disease	44 (9.4)	37 (9.0)	35 (9.0)	58 (13.5)
Diabetes mellitus	73 (15.5)	34 (8.3)	30 (7.7)	63 (14.6)
Subjects without underlying at-risk medical conditions, n (%)	345 (73.4)	329 (80.0)	322 (83.0)	278 (64.5)

Abbreviations: PCV13=13-valent pneumococcal conjugate vaccine; PPSV23=23-valent pneumococcal polysaccharide vaccine; ^aNumber of subjects in the vaccine group; ^bMean age at time of PCV13 vaccination; ^cSubjects may be included in >1 at-risk category.

Supplementary Figure 1

